C4 Therapeutics(CCCC) GlobeNewswire·2025-01-14 12:00Core Insights - C4 Therapeutics is advancing its clinical programs, particularly focusing on cemsidomide, CFT1946, and CFT8919, with significant milestones anticipated in 2025 [2][3][4] Cemsidomide - Cemsidomide is an oral degrader targeting IKZF1/3 for treating relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma, with data presented at the ASH Annual Meeting indicating a 36% overall response rate (ORR) at a dose of 75 µg once daily [4][13] - The company plans to initiate the next phase of clinical development for cemsidomide in combination with dexamethasone and other agents in early 2026 [6] CFT1946 - CFT1946 is an oral degrader targeting BRAF V600 mutations for solid tumors, with ongoing Phase 1/2 studies showing initial signs of anti-tumor activity [5][9] - Data from the Phase 1 dose escalation study is expected to be presented in the second half of 2025, including results from various cohorts [6][13] CFT8919 - CFT8919 targets EGFR with the L858R mutation for non-small cell lung cancer, with a Phase 1 trial ongoing in Greater China led by Betta Pharmaceuticals [7][10] - The data from this trial will inform future development plans for CFT8919 [6][7] Financial Outlook - C4 Therapeutics expects its cash reserves to fund operations into 2027, supported by anticipated collaboration reimbursements [14] Corporate Developments - The company has strengthened its leadership team and Board of Directors to support its evolution into a fully integrated biotechnology company [11][21]